CARCINOMA, RENAL CELL

This study tests whether adding two new drugs (belzutifan and lenvatinib, or a pembrolizumab/quavonlimab combo with lenvatinib) to standard treatment can help Chinese patients with advanced clear cell kidney cancer live longer and slow tumor growth. About 249 participants will re…

This early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…

This study tests whether adding a new drug (belzutifan or quavonlimab) to a standard two-drug therapy helps people with advanced clear cell kidney cancer live longer or keep their cancer from growing. About 1,650 adults who have not had prior treatment for advanced disease will b…

This study tests whether adding belzutifan (a pill) to standard immunotherapy (pembrolizumab) can better prevent kidney cancer from returning after surgery to remove the kidney. About 1,800 adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrenc…

This study tests a new drug called belzutifan against an older drug, everolimus, in 755 people with advanced kidney cancer that got worse after prior treatments. The goal is to see if belzutifan can slow cancer growth or help people live longer. Participants must have a specific …

This study tests experimental combinations of drugs for people with advanced kidney cancer (clear cell renal cell carcinoma) that has spread and hasn't been treated yet. About 400 participants will receive the drug combinations to see if they are safe and help shrink tumors. The …

This phase 3 study tests whether a new drug combination (belzutifan + lenvatinib) works better than the current standard drug (cabozantinib) for people with advanced kidney cancer that has gotten worse after prior immunotherapy. About 747 participants will receive either the comb…

This study tests a new drug, savolitinib, against a standard treatment, sunitinib, for people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib works better at slowing cancer growth and to check its …

This study is for people with advanced kidney cancer that has gotten worse after initial treatment. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 370 participants will receive experimental treatments, and researchers will monitor side eff…

This study aims to understand how the immune system changes in people with kidney or bladder cancer when they receive immunotherapy. Researchers will measure different immune cells and tumor cells in the blood before and during treatment. The goal is to learn more about how these…